Asset
Maralixibat chloride
Mirum Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02117713 | phase2 | completed | 2015-03-16 | 2020-06-01 | Mirum Pharmaceuticals, Inc. | An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome |
| NCT02047318 | phase2 | completed | 2013-12-20 | 2020-06-17 | Mirum Pharmaceuticals, Inc. | An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS) |
| NCT02321306 | phase2 | withdrawn | 2015-05-01 | 2017-12-01 | Mirum Pharmaceuticals, Inc. | An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis |
| NCT02057692 | phase2 | completed | 2014-11-24 | 2016-11-16 | Mirum Pharmaceuticals, Inc. | Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome |
| NCT02057718 | phase2 | completed | 2014-03-01 | 2020-05-08 | Mirum Pharmaceuticals, Inc. | Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis |
FDA applications (2)
| Application | Type | Applicant |
|---|---|---|
| NDA 214662 | NDA | MIRUM PHARMACEUTICALS INC |
| NDA 219485 | NDA | MIRUM PHARMACEUTICALS INC |
Marketed products (6)
- LIVMARLI
- LIVMARLI
- LIVMARLI
- LIVMARLI
- LIVMARLI
- LIVMARLI